Monte Rosa Therapeutics I... (GLUE)
NASDAQ: GLUE
· Real-Time Price · USD
11.11
0.50 (4.71%)
At close: Oct 15, 2025, 3:59 PM
10.89
-1.98%
After-hours: Oct 15, 2025, 04:14 PM EDT
4.71% (1D)
| Bid | 10.6 |
| Market Cap | 686.15M |
| Revenue (ttm) | 177.99M |
| Net Income (ttm) | 24.17M |
| EPS (ttm) | 0.39 |
| PE Ratio (ttm) | 28.49 |
| Forward PE | -7.65 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 11.18 |
| Volume | 1,302,475 |
| Avg. Volume (20D) | 1,207,000 |
| Open | 10.75 |
| Previous Close | 10.61 |
| Day's Range | 10.45 - 11.13 |
| 52-Week Range | 3.50 - 12.40 |
| Beta | 1.54 |
| Ex-Dividend Date | n/a |
About GLUE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GLUE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GLUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMonte Rosa Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+44.07%
Monte Rosa Therapeutics shares are trading higher ...
Unlock content with
Pro Subscription
3 weeks ago · seekingalpha.com
Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POCMonte Rosa secured a second major Novartis deal, adding $120M upfront and up to $5.7B in milestones to its cash reserves. GLUE advances MRT-8102, a NEK7 molecular glue degrader, into Phase 1 trials ta...
4 weeks ago · seekingalpha.com
Monte Rosa Therapeutics And The Promise Of Molecular Glue DegradersMonte Rosa Therapeutics shares jumped this week after the company expanded its collaboration with Novartis. The Novartis partnership brings significant upfront cash and external QuEEN platform validat...
